A research group comprising Keio University School of Medicine’s Department of Nephrology, Endocrinology and Metabolism, Department of Ophthalmology, and Department of Pharmacology, together with researchers at Washington University School of Medicine in St. Louis has initiated the world’s first clinical study of the administration in humans of nicotinamide mononucleotide (NMN), a compound thought to regulate aging.
Previous studies have demonstrated that administration of NMN in animals increases nicotinamide adenine dinucleotide (NAD) levels in various organs, ameliorating the symptoms of age-related diseases. However, the safety and efficacy of NMN have not yet been assessed in humans. The purpose of this clinical study is to assess the safety of NMN in humans and clarify the mechanisms by which NMN contributes to NAD synthesis. The ultimate aim of studying the safety and pharmacokinetics of NMN in humans is to uncover ways to treat, or preferably prevent, age-related diseases in the future.
For further information, please refer to the following PDF file.
The World’s First Human Clinical Study of the Age-Regulating Compound Nicotinamide Mononucleotide
